Dr Reddys Laboratories Ltd Share Price (DRREDDY)
₹5957.15
Dr Reddys Laboratories Ltd share Performance
- ₹5937.65₹6127.5₹5957.15
0.33%
Low
Day's Volatility:3.19%
High
2.86%
- ₹4384.05₹6505.9₹5957.15
26.41%
Low
52 Weeks Volatility:35.62%
High
9.21%
| Returns % | |
| 1 Month Return | -4.58 % |
| 3 Month Return | 7.09 % |
| 1 Year Return | 23.16 % |
| Market Stats | |
| Previous Close | ₹6,050.35 |
| Open | ₹6,099.95 |
| Volume | 5.98L |
| Upper Circuit | - |
| Lower Circuit | - |
| Market Cap | ₹1,00,930.89Cr |
Analyst Rating for Dr Reddys Laboratories Ltd stock
based on 35 analysts
Based on 35 analysts offering long term price targets for Dr Reddys Laboratories Ltd. An average target of ₹6017.31
Source: S&P Global Market Intelligence
Company Information
Dr Reddy's Laboratories Ltd has a diverse portfolio of products and services, including prescription drugs, generic drugs, over-the-counter drugs, active pharmaceutical ingredients, biotechnology products, and nutraceuticals. Its most popular products include antibiotics, anti-infectives, anti-diabetics, anti-cancer, cardiovascular, gastrointestinal, and dermatology products. Some of its popular brands include Omez, Ciprocin, and Revital. It also has a strong presence in the generics market with its brands such as Reditux and Reditux-D.
Share Price: ₹5957.15 per share as on 18 Apr, 2024 04:01 PM
Market Capitalisation: ₹1,00,930.89Cr as of today
Revenue: ₹7,214.80Cr as on December 2023 (Q4 23)
Net Profit: ₹1,380.90Cr as on December 2023 (Q4 23)
Listing date: 03 Nov, 1994
Chairperson Name: K Satish Reddy
| Organisation | Dr Reddys Laboratories Ltd |
| Headquarters | Hyderabad |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
Key events for Dr Reddys Laboratories Ltd
Dr. Reddy's Laboratories Ltd has a lower P/E ratio than the market average - 18 Apr, 2024
Dr. Reddy's Laboratories Ltd has been performing well with superior earnings growth compared to most other companies, but investors think this strong earnings performance might be less impressive moving forward. The company grew EPS by 43% last year and is estimated to generate growth of 2.7% per annum in the next three years as forecasted by analysts. However, unless these conditions improve, they will continue to form a barrier for the share price around current levels.
Dr Reddys Launches Migraine Management Device in Europe - 12 Apr, 2024
Dr Reddys Laboratories has launched Nerivio, a drug-free migraine management device in Germany via its subsidiary Betapharm. The wearable device is approved by the USFDA and CE-mark certified in Europe. Following its European debut, it will be launched in South Africa later this month, with subsequent introductions in Spain and the UK.
Dr. Reddy's Launches Migraine Management Wearable Device in Europe - 11 Apr, 2024
Dr. Reddy's Laboratories has entered the digital therapeutics market in Europe with the launch of Nerivio, a non-invasive migraine management wearable device approved by the USFDA and CE-mark certified in Europe. The company plans to launch the product in South Africa later this month and subsequently in Spain and the UK.
Dr. Reddy's Launches Migraine Management Device in Europe - 10 Apr, 2024
Dr. Reddy's Laboratories has launched its non-invasive migraine management wearable device, Nerivio, in Germany through its subsidiary Betapharm. The launch marks the company's entry into digital therapeutics in Europe and is approved by the USFDA and CE-mark certified.
Dr. Reddy's Labs Expected to Post Strong Q4 Results - 09 Apr, 2024
Analysts forecast a 14-15% YoY revenue growth for Indian pharma companies in Q4FY24, with MOSL predicting strong results for Dr. Reddy's Labs due to robust domestic business and US sales growth.
Sanofi Forms Strategic Alliances with Indian Pharma Firms - 07 Apr, 2024
Sanofi has partnered with Cipla, Dr. Reddys Laboratories, and Emcure to expand its market reach in India. The collaborations aim to maximize the impact of Sanofi's existing products.
Dr. Reddy's Partners with Bayer for Vericiguat Distribution - 06 Apr, 2024
Dr. Reddy's Laboratories has entered into a partnership agreement with Bayer to market and distribute Vericiguat, a medication used to reduce the risk of cardiovascular death and hospitalization in certain patients with heart failure after a recent acute decompensation event, in India under the brand name Gantra.
Dr Reddys Partners with Bayer for Heart Failure Medication - 05 Apr, 2024
Dr Reddys Laboratories has partnered with Bayer to introduce a second brand of Vericiguat, a medication for chronic heart failure, to the Indian market. The partnership will expand access to this treatment for a wider range of patients in India.
Sharekhan Reiterates Buy Rating on Dr. Reddy's Laboratories - 02 Apr, 2024
Dr. Reddy's Laboratories is expected to see growth momentum led by Horizon 1 and Horizon 2 strategy, with North America projected to grow at a CAGR of 7% from FY24-26E driven by new product launches in the generics segment, gRevlimid and biosimilar launches. India sales are also expected to grow in double digits. Sharekhan maintains a Buy rating with a PT of Rs. 6,537.
Dr Reddys Subsidiary Plans Biologics Expansion - 01 Apr, 2024
Dr Reddys subsidiary Aurigene Pharmaceutical Services is set to expand into biologics with a new facility in Hyderabad. Meanwhile, the pharmaceuticals and drugs sector has exceeded investment expectations, benefiting companies such as Dr Reddys.
Dr. Reddy's Laboratories ROE and Earnings Growth Studied - 30 Mar, 2024
A recent study of Dr. Reddy's Laboratories' fundamentals, including its return on equity (ROE), earnings growth, and payout ratio, suggests that the company may be influencing the market. The stock has seen a 6.2% increase over the past three months.
Dr Reddy's Laboratories Reports Increase in Revenue and Profitability Metrics - 29 Mar, 2024
Dr Reddy's Laboratories reported a 5% increase in revenue from Rs. 6,903 crores to Rs. 7,237 crores in the December quarter, while net profits decreased by 7%. However, profitability metrics improved with RoE increasing from 11.84% to 21.21%, RoCE zooming from 14.46% to 25.99%, and net profit margin increasing from 10.13% to 18.27% on a YoY basis.
Dr Reddys Forms Exclusive Alliance with Sanofi for Vaccine Distribution - 28 Mar, 2024
Dr Reddys Laboratories has entered into an exclusive distribution partnership with Sanofi Healthcare India to promote and distribute their vaccine brands across private markets in India. This will give Dr Reddys a strong presence in the vaccine segment, propelling them to the second position among vaccines players in India.
Dr. Reddys Enters Exclusive Partnership for Vaccine Distribution - 27 Mar, 2024
Dr. Reddys Laboratories has signed an exclusive partnership with Sanofi Healthcare India to promote and distribute their vaccine brands across India's private markets, propelling them to second place among vaccine players in India.
Dr. Reddys Licenses First-in-Class Drug for Indian Market - 26 Mar, 2024
Dr. Reddys Laboratories has entered into a license agreement with US-based company Pharmazz to market and distribute Centhaquine, a first-in-class resuscitative agent, in India and Nepal under the brand name Lyfaquin.
Dr Reddy's to Commercialize Centhaquine in India - 25 Mar, 2024
Dr Reddy's Laboratories has entered into a license agreement with US-based Pharmazz Inc. to commercialize centhaquine, an innovative drug used for the treatment of hypovolemic shock, in India.
Dr. Reddy's Licenses Centhaquine for Indian Market - 22 Mar, 2024
Dr. Reddy's Laboratories has entered into a licensing agreement with US-based biopharma company, Pharmazz Inc., to market and distribute Centhaquine (Lyfaquin) as a resuscitative agent for hypovolemic shock in India. Dr. Reddy's will own the brand name Lyfaquin and receive exclusive rights to market and distribute Centhaquine in India and Nepal.
Fundamentals of Dr Reddys Laboratories Ltd
Insights on Dr Reddys Laboratories Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTRetail Holding Up
Retail Investor have increased holdings from 9.91% to 10.57% in Dec 2023 quarter
- POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 4 quarters, 6.46K Cr → 7.45K Cr (in ₹), with an average increase of 4.7% per quarter
- POSITIVE IMPACT
FII Holding Up
Foreign Institutions have increased holdings from 28.20% to 28.62% in Dec 2023 quarter
NO EFFECTAgainst Peers
In the last 3 years, Sun Pharmaceuticals Industries Ltd has given 140.0% return, outperforming this stock by 118.2%
- NO EFFECT
Against Peers
In the last 1 year, Sun Pharmaceuticals Industries Ltd has given 53.0% return, outperforming this stock by 29.9%
NEGATIVE IMPACTMF Holding Down
Mutual Funds have decreased holdings from 8.61% to 8.22% in Dec 2023 quarter
- NEGATIVE IMPACT
Promoter Holding Down
Promoters have decreased holdings from 26.66% to 26.65% in Dec 2023 quarter
- NEGATIVE IMPACT
Profit Down
Netprofit is down for the last 2 quarters, 1.48K Cr → 1.38K Cr (in ₹), with an average decrease of 6.8% per quarter
- NEGATIVE IMPACT
Price Dip
In the last 1 month, DRREDDY stock has moved down by -4.6%
Dr Reddys Laboratories Ltd Valuation
Dr Reddys Laboratories Ltd in the last 5 years
Lowest (15.84x)
October 7, 2019
Today (19.25x)
April 16, 2024
Industry (60.97x)
April 16, 2024
Highest (53.88x)
December 18, 2020
Mutual Fund Holdings
| Funds | Holdings |
 HDFC Flexi Cap Fund -Direct Plan - Growth Option | 1.33% |
 Parag Parikh Flexi Cap Direct Growth | 1.02% |
 Nippon India Pharma Fund - Direct Plan - Growth Plan | 4.75% |
| HDFC ELSS TaxSaver -Direct Plan - Growth Option | 1.98% |
 ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth | 7.19% |
Shareholding Pattern
| Investors | Holdings % | Prev. 4 periods | 3M change |
|---|---|---|---|
| Promoter Holdings | 26.65% | ||
| Foreign Institutions | 28.62% | 1.52 | |
| Mutual Funds | 8.21% | ||
| Retail Investors | 10.57% | 6.56 | |
| Others | 25.94% |
Technicals of Dr Reddys Laboratories Ltd share
News & Events of Dr Reddys Laboratories Ltd
News
ZEE's Amit Goenka, Umesh Bansal: Who are the top leaders after Punit Goenka shuffles ranks?
Punit Goenka himself will assume direct charge of all the critical business verticals including the Domestic Broadcast Business.
18 Apr, 2024 11:26 AMShare price of Zee Ent. falls as Nifty weakens
A total of 399,681 shares changed hands on the counter till 01:49PM (IST).
18 Apr, 2024 01:49 PMZee Entertainment Enterprises, SAIL among 5 stocks with top long unwinding
Long unwinding refers to selling of positions or stocks owned for a longer period either to book profit or to exit it in anticipation of impending bearishness. ... Read more
18 Apr, 2024 05:32 PMFrequently Asked Questions
- Get a PAN card.
- Open a Demat account.
- Open a Trading account.
- Link your Demat account to your Trading account.
- Fund your Trading account.
- Place an order to buy Dr Reddys Laboratories Ltd shares.
Dr Reddys Laboratories Ltd (DRREDDY) share price today is ₹5957.15
Dr Reddys Laboratories Ltd is listed on NSE
Dr Reddys Laboratories Ltd is listed on BSE
- Today’s highest price of Dr Reddys Laboratories Ltd is ₹6127.5.
- Today’s lowest price of Dr Reddys Laboratories Ltd is ₹5937.65.
PE Ratio of Dr Reddys Laboratories Ltd is 19.25
PE ratio = Dr Reddys Laboratories Ltd Market price per share / Dr Reddys Laboratories Ltd Earnings per share
Today’s traded volume of Dr Reddys Laboratories Ltd(DRREDDY) is 5.98L.
Today’s market capitalisation of Dr Reddys Laboratories Ltd(DRREDDY) is ₹100930.89Cr.
| Dr Reddys Laboratories Ltd(DRREDDY | Price |
|---|---|
52 Week High | ₹6505.9 |
52 Week Low | ₹4384.05 |
Dr Reddys Laboratories Ltd(DRREDDY) share price is ₹5957.15. It is down -8.43% from its 52 Week High price of ₹6505.9
Dr Reddys Laboratories Ltd(DRREDDY) share price is ₹5957.15. It is up 35.88% from its 52 Week Low price of ₹4384.05
| Dr Reddys Laboratories Ltd(DRREDDY | Returns |
|---|---|
1 Day Returns | -93.2% |
1 Month Returns | -4.58% |
3 Month Returns | 7.09% |
1 Year Returns | 23.16% |